Acumen Pharmaceuticals (ABOS) Income Statement: Revenue & Earnings

Acumen Pharmaceuticals Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Acumen Pharmaceuticals, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	0.00	0.01	0.04	0.07	1.44
Cost of Revenue	0.00	42.32	32.36	12.31	8.00
Gross Profit	0.00	-42.32	0.04	0.07	-6.56
Operating Expenses
Research & Development	93.80	42.32	32.36	12.31	0.00
Selling, General & Administrative	20.22	18.82	12.88	7.28	1.35
Operating Expenses	114.02	61.14	45.24	19.58	1.35
Operating Income	-114.02	-61.14	-45.24	-19.58	-7.91
Other Income/Expense
Interest Income	14.32	10.79	2.39	0.08	0.00
Interest Expense	4.07	0.58	0.00	0.00	0.00
Other Income/Expense	1.44	-1.44	-0.01	81.11	0.59
Income
Income Before Tax	-102.33	-52.37	-42.86	-100.61	-7.33
Income Tax Expense	0.00	0.00	0.00	0.00	0.00
Net Income	-102.33	-52.37	-42.86	-100.61	-7.33
Net Income - Continuous Operations	-102.33	-52.37	-42.86	-100.61	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-98.08	-51.61	-42.69	-100.45	0.00
EBIT	-98.26	-51.79	-42.86	-100.61	-7.91
Depreciation & Amortization	0.18	0.18	0.03	0.00	0.00
Earnings Per Share
Basic EPS	-2.00	-1.00	-1.00	-5.00	-17.00
Diluted EPS	-2.00	-1.00	-1.00	-5.00	-17.00
Basic Shares Outstanding	60.01	48.61	40.60	20.06	0.42
Diluted Shares Outstanding	60.01	48.61	40.60	20.06	0.42